These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 31941080)

  • 1. d-Mannose Treatment neither Affects Uropathogenic
    Scribano D; Sarshar M; Prezioso C; Lucarelli M; Angeloni A; Zagaglia C; Palamara AT; Ambrosi C
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31941080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation.
    Schwartz DJ; Kalas V; Pinkner JS; Chen SL; Spaulding CN; Dodson KW; Hultgren SJ
    Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15530-7. PubMed ID: 24003161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A flow cytometry-based assay for screening FimH antagonists.
    Scharenberg M; Abgottspon D; Cicek E; Jiang X; Schwardt O; Rabbani S; Ernst B
    Assay Drug Dev Technol; 2011 Oct; 9(5):455-64. PubMed ID: 21675870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surfactant protein D inhibits adherence of uropathogenic Escherichia coli to the bladder epithelial cells and the bacterium-induced cytotoxicity: a possible function in urinary tract.
    Kurimura Y; Nishitani C; Ariki S; Saito A; Hasegawa Y; Takahashi M; Hashimoto J; Takahashi S; Tsukamoto T; Kuroki Y
    J Biol Chem; 2012 Nov; 287(47):39578-88. PubMed ID: 23012359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiadhesive natural products against uropathogenic E. coli: What can we learn from cranberry extract?
    Scharf B; Schmidt TJ; Rabbani S; Stork C; Dobrindt U; Sendker J; Ernst B; Hensel A
    J Ethnopharmacol; 2020 Jul; 257():112889. PubMed ID: 32311481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding.
    Chen SL; Hung CS; Pinkner JS; Walker JN; Cusumano CK; Li Z; Bouckaert J; Gordon JI; Hultgren SJ
    Proc Natl Acad Sci U S A; 2009 Dec; 106(52):22439-44. PubMed ID: 20018753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Consumption of Cranberry Exerts ex Vivo Antiadhesive Activity against FimH-Dominated Uropathogenic Escherichia coli: A Combined in Vivo, ex Vivo, and in Vitro Study of an Extract from Vaccinium macrocarpon.
    Rafsanjany N; Senker J; Brandt S; Dobrindt U; Hensel A
    J Agric Food Chem; 2015 Oct; 63(40):8804-18. PubMed ID: 26330108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist.
    Spaulding CN; Klein RD; Ruer S; Kau AL; Schreiber HL; Cusumano ZT; Dodson KW; Pinkner JS; Fremont DH; Janetka JW; Remaut H; Gordon JI; Hultgren SJ
    Nature; 2017 Jun; 546(7659):528-532. PubMed ID: 28614296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic Escherichia coli.
    Greene SE; Hibbing ME; Janetka J; Chen SL; Hultgren SJ
    mBio; 2015 Jun; 6(4):e00820. PubMed ID: 26126855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycosylation changes as important factors for the susceptibility to urinary tract infection.
    Taganna J; de Boer AR; Wuhrer M; Bouckaert J
    Biochem Soc Trans; 2011 Jan; 39(1):349-54. PubMed ID: 21265802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI.
    Jarvis C; Han Z; Kalas V; Klein R; Pinkner JS; Ford B; Binkley J; Cusumano CK; Cusumano Z; Mydock-McGrane L; Hultgren SJ; Janetka JW
    ChemMedChem; 2016 Feb; 11(4):367-73. PubMed ID: 26812660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surface display of uropathogenic Escherichia coli FimH in Lactococcus lactis: In vitro characterization of recombinant bacteria and its protectivity in animal model.
    Derakhshandeh S; Shahrokhi N; Khalaj V; Habibi M; Moazzezy N; Asadi Karam MR; Bouzari S
    Microb Pathog; 2020 Apr; 141():103974. PubMed ID: 31926238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Conformational Variability of FimH: Which Conformation Represents the Therapeutic Target?
    Eris D; Preston RC; Scharenberg M; Hulliger F; Abgottspon D; Pang L; Jiang X; Schwardt O; Ernst B
    Chembiochem; 2016 Jun; 17(11):1012-20. PubMed ID: 26991759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.
    Bouckaert J; Berglund J; Schembri M; De Genst E; Cools L; Wuhrer M; Hung CS; Pinkner J; Slättegård R; Zavialov A; Choudhury D; Langermann S; Hultgren SJ; Wyns L; Klemm P; Oscarson S; Knight SD; De Greve H
    Mol Microbiol; 2005 Jan; 55(2):441-55. PubMed ID: 15659162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The affinity of the FimH fimbrial adhesin is receptor-driven and quasi-independent of Escherichia coli pathotypes.
    Bouckaert J; Mackenzie J; de Paz JL; Chipwaza B; Choudhury D; Zavialov A; Mannerstedt K; Anderson J; Piérard D; Wyns L; Seeberger PH; Oscarson S; De Greve H; Knight SD
    Mol Microbiol; 2006 Sep; 61(6):1556-68. PubMed ID: 16930149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential stability and trade-off effects of pathoadaptive mutations in the Escherichia coli FimH adhesin.
    Weissman SJ; Beskhlebnaya V; Chesnokova V; Chattopadhyay S; Stamm WE; Hooton TM; Sokurenko EV
    Infect Immun; 2007 Jul; 75(7):3548-55. PubMed ID: 17502398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimeric and Trimeric Fusion Proteins Generated with Fimbrial Adhesins of Uropathogenic
    Luna-Pineda VM; Reyes-Grajeda JP; Cruz-Córdova A; Saldaña-Ahuactzi Z; Ochoa SA; Maldonado-Bernal C; Cázares-Domínguez V; Moreno-Fierros L; Arellano-Galindo J; Hernández-Castro R; Xicohtencatl-Cortes J
    Front Cell Infect Microbiol; 2016; 6():135. PubMed ID: 27843814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex.
    Wellens A; Garofalo C; Nguyen H; Van Gerven N; Slättegård R; Hernalsteens JP; Wyns L; Oscarson S; De Greve H; Hultgren S; Bouckaert J
    PLoS One; 2008 Apr; 3(4):e2040. PubMed ID: 18446213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target Selectivity of FimH Antagonists.
    Scharenberg M; Schwardt O; Rabbani S; Ernst B
    J Med Chem; 2012 Nov; 55(22):9810-6. PubMed ID: 23088608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multivalent calix[4]arene-based mannosylated dendrons as new FimH ligands and inhibitors.
    Palmioli A; Moretti L; Vezzoni CA; Legnani L; Sperandeo P; Baldini L; Sansone F; Airoldi C; Casnati A
    Bioorg Chem; 2023 Sep; 138():106613. PubMed ID: 37224739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.